agilon health Inc. reported its second quarter 2025 financial results, revealing total revenues of $1.39 billion, a decrease of 6% compared to $1.48 billion in the same quarter of the previous year. The decline in revenue is attributed to the impact from market exits and a reduction in risk adjustment revenue contribution, despite membership growth in new markets and existing geographies. The company's gross profit turned negative at $52 million for the quarter, contrasting with a positive $32 million in the second quarter of 2024. The net loss for agilon health in the second quarter of 2025 was $104 million, compared to a net loss of $31 million in the same period last year. The company reported a decrease in total platform membership to 614,000 as of June 30, 2025, including 498,000 Medicare Advantage members and 116,000 ACO REACH model beneficiaries. This membership change reflects previously disclosed market exits. Additionally, agilon health announced the suspension of its full-year 2025 earnings guidance due to a leadership change, ongoing performance visibility initiatives, and dynamic market conditions. Steven Sell has stepped down as President, CEO, and a Director of the Board, with the company's co-founder Michael Smith assuming the role of interim CEO. The company is focusing on initiatives to enhance financial and clinical data visibility and improve operational performance.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.